The FDA issued an inspection report revealing an unauthorized warehouse in India holding active pharmaceutical ingredients and finished drugs that was reportedly infested with lizards and cats. The finding raises immediate supply‑chain integrity and good manufacturing practice concerns for a generic manufacturer operating in a complex global API market. Regulators and purchasers will likely review sourcing and supplier audits more aggressively; drugmakers exposed to the site may face delays, corrective actions, and heightened scrutiny from both U.S. and international buyers. The incident underscores persistent vulnerabilities in API storage and distribution oversight.